CA2445746A1 - Chimeric immunoreceptor useful in treating human cancers - Google Patents
Chimeric immunoreceptor useful in treating human cancers Download PDFInfo
- Publication number
- CA2445746A1 CA2445746A1 CA002445746A CA2445746A CA2445746A1 CA 2445746 A1 CA2445746 A1 CA 2445746A1 CA 002445746 A CA002445746 A CA 002445746A CA 2445746 A CA2445746 A CA 2445746A CA 2445746 A1 CA2445746 A1 CA 2445746A1
- Authority
- CA
- Canada
- Prior art keywords
- immunoreceptor
- domain
- chimeric
- transmembrane
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract 9
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 6
- 239000003446 ligand Substances 0.000 claims abstract 7
- 108020003175 receptors Proteins 0.000 claims abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 5
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract 4
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract 4
- 230000004068 intracellular signaling Effects 0.000 claims abstract 3
- 102000004127 Cytokines Human genes 0.000 claims abstract 2
- 108090000695 Cytokines Proteins 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 230000003076 paracrine Effects 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 3
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 2
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000003305 autocrine Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108091008582 intracellular receptors Proteins 0.000 claims 1
- 102000027411 intracellular receptors Human genes 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 abstract 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A61K39/4611—
-
- A61K39/4631—
-
- A61K39/4632—
-
- A61K39/464419—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to chimeric transmembrane immunoreceptors, named "zetakines", comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T
lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13R.alpha.2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13R.alpha.2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
Claims (10)
1. A chimeric immunoreceptor comprising the following linked elements, arranged in the stated order:
a) an extracellular domain comprising a soluble receptor ligand, b) a support region capable of tethering the extracellular domain to a cell surface, c) a transmembrane region, and d) an intracellular signalling domain.
a) an extracellular domain comprising a soluble receptor ligand, b) a support region capable of tethering the extracellular domain to a cell surface, c) a transmembrane region, and d) an intracellular signalling domain.
2. The chimeric immunoreceptor of claim 1, wherein the extracellular domain comprises a soluble ligand selected from the group consisting of autocrine growth factors, paracrine growth factors, chemokines, cytokines, hormones, and engineered artificial small molecule ligands.
3. The chimeric immunoreceptor of claim 1, wherein the support region is selected from the group consisting of the constant regions of immunoglobins, CD8, and artificial linkers.
4. The chimeric immunoreceptor of claim 1, wherein the transmembrane region is a transmembrane domain of a leukocyte CD marker.
5. The chimeric immunoreceptor of claim 1, wherein the intracellular signalling domain is selected from the group consisting of the intracellular receptor signalling domain of the T cell antigen complex, Fc.gamma. RIII
costimulatory domains, CD28, DAP10 and CD2.
costimulatory domains, CD28, DAP10 and CD2.
6. The chimeric immunoreceptor of claim 1, comprising the following linked elements, in the stated order:
a) IL13(E13Y), b) an IgG4 constant region, c) a CD4 transmembrane domain, and d) an intracellular T cell antigen receptor CD3 complex zeta chain.
a) IL13(E13Y), b) an IgG4 constant region, c) a CD4 transmembrane domain, and d) an intracellular T cell antigen receptor CD3 complex zeta chain.
7. The chimeric immunoreceptor of claim 1, wherein the immunoreceptor is expressed by a T lymphocyte cell line transformed with a DNA sequence encoding the immunoreceptor.
8. A method for treating human cancer, comprising administering to a human suffering from cancer a plurality of cells expressing an immunoreceptor of any of claims 1-7, wherein the soluble receptor ligand of the immunoreceptor is specific for a cancer-specific cell surface receptor.
9. The method of claim 8, wherein the the cancer-specific cell surface receptor is a cytokine receptor.
10. The method of claim 9, wherein the soluble receptor ligand is IL-13(E13Y).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28698101P | 2001-04-30 | 2001-04-30 | |
| US60/286,981 | 2001-04-30 | ||
| PCT/US2002/013500 WO2002088334A1 (en) | 2001-04-30 | 2002-04-30 | Chimeric immunoreceptor useful in treating human cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2445746A1 true CA2445746A1 (en) | 2002-11-07 |
| CA2445746C CA2445746C (en) | 2012-09-18 |
Family
ID=23100961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2445746A Expired - Lifetime CA2445746C (en) | 2001-04-30 | 2002-04-30 | Chimeric immunoreceptor useful in treating human cancers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030171546A1 (en) |
| EP (1) | EP1392818A4 (en) |
| JP (2) | JP4448282B2 (en) |
| AU (1) | AU2002256390B2 (en) |
| CA (1) | CA2445746C (en) |
| WO (1) | WO2002088334A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9914909B2 (en) | 2014-09-19 | 2018-03-13 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 |
| US11278594B2 (en) | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| JP5188504B2 (en) | 2006-11-13 | 2013-04-24 | サンガモ バイオサイエンシズ インコーポレイテッド | Methods and compositions for modification of the human glucocorticoid receptor locus |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| KR20100042082A (en) * | 2008-10-15 | 2010-04-23 | 삼성전자주식회사 | Solid support with enhanced density of a signal material, kit containing the same and method for detecting target material using the same |
| SG10201503736XA (en) * | 2010-02-12 | 2015-06-29 | Oncomed Pharm Inc | Methods for identifying and isolating cells expressing a polypeptide |
| KR20140002649A (en) * | 2010-10-27 | 2014-01-08 | 베이롤 칼리지 오브 메드신 | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PL3214091T3 (en) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NZ616405A (en) * | 2011-04-08 | 2015-11-27 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| EP2817331B1 (en) * | 2012-02-22 | 2023-08-30 | The Trustees of the University of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| MY190711A (en) | 2013-02-20 | 2022-05-12 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| ES2814962T3 (en) | 2013-02-20 | 2021-03-29 | Novartis Ag | Efficient targeting of primary human leukemia using anti-CD123 chimeric antigen receptor modified T cells |
| ES2769574T3 (en) | 2013-03-15 | 2020-06-26 | Michael C Milone | Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (en) | 2013-03-16 | 2014-10-31 | Novartis Ag | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER |
| KR102049990B1 (en) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | Fusion protein comprising anti-c-Met antibody and VEGF binding fragment |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CN106459989B (en) | 2013-12-19 | 2023-02-17 | 诺华股份有限公司 | Human mesothelin chimeric antigen receptor and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| MX369513B (en) | 2014-02-14 | 2019-11-11 | Univ Texas | Chimeric antigen receptors and methods of making. |
| EP3888674B1 (en) | 2014-04-07 | 2024-04-03 | Novartis AG | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| CN107109420A (en) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | Use the treatment of cancer of CLL-1 Chimeric antigen receptors |
| JP6831777B2 (en) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Treatment of cancer using the CD33 chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CA2955386A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| CN107108744B (en) | 2014-08-19 | 2020-09-25 | 诺华股份有限公司 | anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy |
| DK3194443T3 (en) | 2014-09-17 | 2021-09-27 | Novartis Ag | TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY |
| JP6815992B2 (en) | 2014-10-08 | 2021-01-20 | ノバルティス アーゲー | Biomarkers predicting therapeutic response to chimeric antigen receptor therapy and their use |
| JP6951973B2 (en) | 2014-11-12 | 2021-10-20 | シージェン インコーポレイテッド | Glycan interacting compounds and how to use |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| RU2021118125A (en) | 2014-12-29 | 2022-04-06 | Новартис Аг | METHODS FOR OBTAINING EXPRESSING CHIMERIC ANTIGENIC RECEPTOR CELLS |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| TWI746437B (en) | 2015-04-08 | 2021-11-21 | 瑞士商諾華公司 | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| ES2948133T3 (en) | 2015-04-17 | 2023-08-31 | Novartis Ag | Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| CN108780084B (en) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | Biomarkers predictive of cytokine release syndrome |
| JP7066613B2 (en) | 2015-11-12 | 2022-05-13 | シージェン インコーポレイテッド | Glycan interacting compounds and how to use |
| BR112018011089A2 (en) | 2015-12-04 | 2018-12-04 | Intellia Therapeutics Inc | compositions and methods for immuno-oncology |
| WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| TWI797091B (en) | 2016-10-07 | 2023-04-01 | 瑞士商諾華公司 | Treatment of cancer using chimeric antigen receptors |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
| ES2912408T3 (en) | 2017-01-26 | 2022-05-25 | Novartis Ag | CD28 compositions and methods for therapy with chimeric receptors for antigens |
| WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| EP3589295B1 (en) | 2017-02-28 | 2024-09-11 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| JP2020510671A (en) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | Glycan interacting compounds and methods of use |
| JP2020513832A (en) | 2017-03-22 | 2020-05-21 | ノバルティス アーゲー | Compositions and methods for immunooncology |
| EP3648786A4 (en) * | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
| BR112020007576A2 (en) | 2017-10-18 | 2020-09-24 | Novartis Ag | compositions and methods for selective protein degradation |
| JP7417542B2 (en) | 2018-01-22 | 2024-01-18 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | How to use CAR T cells |
| MX2020013443A (en) | 2018-06-13 | 2021-02-26 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof. |
| US20220025025A1 (en) * | 2018-10-09 | 2022-01-27 | Ibex Biosciences, Llc | Antibodies directed to filamin-a and therapeutic uses thereof |
| AR120563A1 (en) | 2019-11-26 | 2022-02-23 | Novartis Ag | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES |
| WO2021244486A1 (en) * | 2020-06-01 | 2021-12-09 | 上海君赛生物科技有限公司 | Signal conversion receptor and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015628A (en) * | 1986-06-12 | 1991-05-14 | The University Of Melbourne | Anticariogenic phosphopeptides |
| US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
| AU643109B2 (en) * | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| DE4120325A1 (en) * | 1991-06-20 | 1992-12-24 | Merck Patent Gmbh | IMPLANT MATERIAL |
| US5514378A (en) * | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5522895A (en) * | 1993-07-23 | 1996-06-04 | Rice University | Biodegradable bone templates |
| US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
| US6065476A (en) * | 1994-12-21 | 2000-05-23 | Board Of Regents, University Of Texas System | Method of enhancing surface porosity of biodegradable implants |
| JP2653423B2 (en) * | 1995-03-29 | 1997-09-17 | 工業技術院長 | Calcium phosphate compound-cellulose fiber composite material and method for producing the same |
| JP2862509B2 (en) * | 1996-05-28 | 1999-03-03 | 東洋電化工業株式会社 | Carrier for lipase immobilization and immobilized lipase |
| US5837674A (en) * | 1996-07-03 | 1998-11-17 | Big Bear Bio, Inc. | Phosphopeptides and methods of treating bone diseases |
| US6281257B1 (en) * | 1998-04-27 | 2001-08-28 | The Regents Of The University Of Michigan | Porous composite materials |
| WO2000023573A2 (en) * | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6165486A (en) * | 1998-11-19 | 2000-12-26 | Carnegie Mellon University | Biocompatible compositions and methods of using same |
-
2002
- 2002-04-30 EP EP02725851A patent/EP1392818A4/en not_active Withdrawn
- 2002-04-30 JP JP2002585615A patent/JP4448282B2/en not_active Expired - Lifetime
- 2002-04-30 WO PCT/US2002/013500 patent/WO2002088334A1/en not_active Application Discontinuation
- 2002-04-30 CA CA2445746A patent/CA2445746C/en not_active Expired - Lifetime
- 2002-04-30 US US10/134,645 patent/US20030171546A1/en not_active Abandoned
- 2002-04-30 AU AU2002256390A patent/AU2002256390B2/en not_active Expired
-
2009
- 2009-10-15 JP JP2009238358A patent/JP2010047591A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278594B2 (en) | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US9914909B2 (en) | 2014-09-19 | 2018-03-13 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 |
| US10676717B2 (en) | 2014-09-19 | 2020-06-09 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1392818A1 (en) | 2004-03-03 |
| AU2002256390B9 (en) | 2002-11-11 |
| JP2004528848A (en) | 2004-09-24 |
| JP2010047591A (en) | 2010-03-04 |
| WO2002088334A1 (en) | 2002-11-07 |
| EP1392818A4 (en) | 2005-01-05 |
| AU2002256390B2 (en) | 2007-08-30 |
| CA2445746C (en) | 2012-09-18 |
| US20030171546A1 (en) | 2003-09-11 |
| JP4448282B2 (en) | 2010-04-07 |
| WO2002088334A9 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2445746A1 (en) | Chimeric immunoreceptor useful in treating human cancers | |
| CA2312667C (en) | Novel cytokine | |
| CA2429027C (en) | Antibodies against human receptor h4-1bb | |
| Godfrey et al. | Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. | |
| HintZen et al. | Characterization of the human CD27 ligand, a novel member of the TNF gene family. | |
| Perussia et al. | Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene. | |
| AU680102B2 (en) | Method of preventing or treating disease characterized by neoplastic cells expressing CD40 | |
| AU752433B2 (en) | Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use | |
| Ashkenazi et al. | Immunoadhesins as research tools and therapeutic agents | |
| CN111511763A (en) | CD8 binding agents | |
| WO2007059298B1 (en) | Chimeric immunoreceptor useful in treating human cancers | |
| CA3127025A1 (en) | Gprc5d chimeric antigen receptors and cells expressing the same | |
| Agematsu et al. | Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. | |
| AU762574B2 (en) | Method of inhibiting osteoclast activity | |
| Bigler et al. | S152 (CD27). A modulating disulfide-linked T cell activation antigen. | |
| Fitch | T-cell clones and T-cell receptors | |
| EP1243597B1 (en) | Receptors for human interleukin-12 | |
| JPWO2020018825A5 (en) | ||
| Digel et al. | Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo | |
| NZ264003A (en) | Interleukin-12 receptor protein and dna, immunoglobulin capable of binding the protein and pharmaceutical compositions | |
| Yssel et al. | Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones | |
| Arima et al. | The IL-2 receptor alpha-chain alters the binding of IL-2 to the beta-chain. | |
| Eshel et al. | Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing | |
| Nishimoto et al. | Myeloma biology and therapy: present status and future developments | |
| Stockinger et al. | Human blood basophils synthesize interleukin-2 binding sites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220502 |
|
| MKEX | Expiry |
Effective date: 20220502 |